The use of pindolol with fluoxetine in the treatment of major depression: Final results from a double-blind, placebo-controlled trial

Biological Psychiatry

Volumn 45, Issue 9, 1999, Pages 1170-1177

  Berman, Robert M ^a,b   Anand, Amit ^a,b   Cappiello, Angela ^a,b   Miller, Helen L ^a,b   Hu, X Sylvia ^a,b   Oren, Dan A ^a,b   Charney, Dennis S ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Controlled trial; Fluoxetine; Pindolol; Serotonin receptors

Indexed keywords

FLUOXETINE; PINDOLOL; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MIXTURE; DRUG SCREENING; EDEMA; FEMALE; HAIR LOSS; HUMAN; HYPERTENSION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SINGLE BLIND PROCEDURE; SKIN ALLERGY; THORAX PAIN; TREATMENT OUTCOME;

ADULT; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PINDOLOL;

EID: 0033135316     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00383-7     Document Type: Article

References (26)

1. Artigas F., Perez V., Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry. 51:1994;248-251.
2. 1A antagonists. Trends Neurosci. 19:1996;378-383.
3. Beck A., Ward C., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 4:1961;561-571.
4. Berman R., Charney D., Krystal J. Mechanism of action of antidepressants: Monoamine hypotheses and beyond. Watson S. Biology of Schizophrenia and Affective Disease. 1996;Raven Press, New York.
5. Berman R., Darnell A., Miller H., Anand A., Charney D. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: A double-blind, placebo-controlled trial. Am J Psychiatry. 154:1997;37-43.
6. Blier P., Bergeron P. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol. 15:1995;217-222.
7. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci. 15:1994;220-226.
8. Bordet R., Thomas P., Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: Intermediate analysis of a double-blind, placebo-controlled trial. Am J Psychiatry. 155:1998;1346-1351.
9. 1A receptors. Neurochem Res. 21:1996;557-562.
10. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 32:1959;50-55.
11. 1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: A microdialysis study. J Neurochem. 60:1993;776-779.
12. 1B autoreceptor blocking properties of the beta adrenoceptor antagonist (-)penbutolol. J Pharmacol Exp Ther. 265:1993;707-712.
13. Hoyer D. 5-HT receptors: Subtypes and second messengers. J Recept Res. 11:1991;197-214.
14. 3H]ketanserin. Eur J Pharmacol. 118:1985;13-25.
15. 1A receptor activation in humans. Eur J Clin Pharmacol. 39:1990;17-19.
16. Mazure C., Nelson J., Price L. Reliability and validity of the symptoms of major depressive illness. Arch Gen Psychiatry. 43:1986;451-456.
17. Middlemiss D., Neill J., Tricklebank M. Subtypes of the 5-HT receptor involved in hypothermia and forepaw treading induced by 8-OH-DPAT. Br J Pharmacol. 85:1985;251P.
18. Perez V., Gilaberte I., Faries D., Alvarez E., Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 349:1997;1594-1597.
19. Peroutka S. Antimigraine drug interactions with serotonin receptor subtypes in human brain. Ann Neurol. 23:1988;500-504.
20. Pocock S.J. Group sequential methods in the design and analysis of clinical trials. Biometrika. 64:1977;191-199.
21. Romero L., Bel N., Artigas F., de Montigny C., Blier P. Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: In vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology. 15:1996;349-360.
22. 1A receptor activation by flesinoxan in humans. Neuropsychopharmacology. 13:1995;93-104.
23. Spitzer R., Williams J., Gibbon M., First M. User's Guide for the Structured Clinical Interview for DSM-III-R (SCID). 1990;American Psychiatric Press, Washington, DC.
24. Tome M.B., Isaac M.T., Harte R., Holland C. Paroxetine and pindolol - A randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol. 12:1997;81-89.
25. Woods S., Charney D., Goodman W., Heninger G. Carbon dioxide-induced anxiety. Arch Gen Psychiatry. 45:1988;43-52.
26. Zanardi R., Artigas F., Franchini L., et al. How long should pindolol be associated with paroxetine to improve the antidepressant response? J Clin Psychopharmacol. 17:1997;446-450.